INVA | Innoviva, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	17.36 - 17.68
52 Week Range	14.33 - 21.28
Beta	0.51
Implied Volatility	52.77%
IV Rank	46.00%
Day's Volume	792,379
Average Volume	754,872
Shares Outstanding	62,675,500
Market Cap	1,091,807,210
Sector	Healthcare
Industry	Biotechnology
IPO Date	2004-10-05

Valuation
Profitability
Growth
Health
P/E Ratio	48.39
Forward P/E Ratio	N/A
EPS	0.36
1YR Price Target	17.75
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	112
Country	USA
Website	INVA

Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline.

INVA's peers: GTX, EFTR, PLX, PDSB, LIFE, ELEV, DAWN, MRTX, AMLX, TERN, APLS, XFOR, INZY, HOOK, ABOS, FOLD, INCY, DNLI, ARGX, HRMY

*Chart delayed

Analyzing fundamentals for INVA we got that it has average fundamentals where Valuation is considered to be undervalued, Profitability is moderate, Growth is bad and Health is strong. For more detailed analysis please see INVA Fundamentals page.

Watching at INVA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on INVA Technicals page.